Glucagon-Like Peptide 1 Agonists Market Report: Trends, Forecast and Competitive Analysis to 2030

Glucagon-Like Peptide 1 Agonists Trends and Forecast

The future of the global glucagon-like peptide 1 agonists market looks promising with opportunities in the hospital and specialty clinic markets. The global glucagon-like peptide 1 agonists market is expected to reach an estimated $25.1 billion by 2030 with a CAGR of 6.0% from 2024 to 2030. The major drivers for this market are increase in the cases of type 2 diabetes, obesity and related disorders, increasing adaptation of unhealthy lifestyle and genetic history of diabetes disorders, as well as, growing aging population.

A more than 150-page report is developed to help in your business decisions.

Glucagon-Like Peptide 1 Agonists by Segment

The study includes a forecast for the global glucagon-like peptide 1 agonists by drug type, brand, route of administration, end use, and region.

Glucagon-Like Peptide 1 Agonists Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

• Exenatide
• Liraglutide
• Lixisenatide
• Dulaglutide

Glucagon-Like Peptide 1 Agonists Market by Brand [Shipment Analysis by Value from 2018 to 2030]:

• Byetta
• Bydureon
• Victoza
• Trulicity
• Lyxumia

Glucagon-Like Peptide 1 Agonists Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

• Oral
• Parenteral
• Others

Glucagon-Like Peptide 1 Agonists Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Specialty Clinics
• Others

Glucagon-Like Peptide 1 Agonists Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Glucagon-Like Peptide 1 Agonists Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies glucagon-like peptide 1 agonists companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the glucagon-like peptide 1 agonists companies profiled in this report include-

• F. Hoffmann-La Roche
• Bristol-Myers Squibb Company
• Astrazeneca
• Pfizer
• Baxter
• Hikma Pharmaceuticals
• Amneal Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharmaceuticals
• Mylan

Glucagon-Like Peptide 1 Agonists Market Insights

Lucintel forecasts that dulaglutide will remain the largest segment over the forecast period due to growing obesity rates, and increasing genetic risk factors for type 2 diabetes.

North America will remain the largest region over the forecast period due to the expansion of research and development, as well as growing healthcare facilities in the region.

Features of the Global Glucagon-Like Peptide 1 Agonists Market

Market Size Estimates: Glucagon-like peptide 1 agonists market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Glucagon-like peptide 1 agonists market size by various segments, such as by drug type, brand, route of administration, end use, and region in terms of value ($B).

Regional Analysis: Glucagon-like peptide 1 agonists market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug type, brand, route of administration, end use, and regions for the glucagon-like peptide 1 agonists market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the glucagon-like peptide 1 agonists market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the glucagon-like peptide 1 agonists market size?

Answer: The global glucagon-like peptide 1 agonists market is expected to reach an estimated $25.1 billion by 2030.

Q2. What is the growth forecast for glucagon-like peptide 1 agonists market?

Answer: The global glucagon-like peptide 1 agonists market is expected to grow with a CAGR of 6.0% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the glucagon-like peptide 1 agonists market?

Answer: The major drivers for this market are increase in the cases of type 2 diabetes, obesity and related disorders, increasing adaptation of unhealthy lifestyle and genetic history of diabetes disorders, as well as, growing aging population.

Q4. What are the major segments for glucagon-like peptide 1 agonists market?

Answer: The future of the global glucagon-like peptide 1 agonists market looks promising with opportunities in the hospital and specialty clinic markets.

Q5. Who are the key glucagon-like peptide 1 agonists market companies?

Answer: Some of the key glucagon-like peptide 1 agonists companies are as follows.

• F. Hoffmann-La Roche
• Bristol-Myers Squibb Company
• Astrazeneca
• Pfizer
• Baxter
• Hikma Pharmaceuticals
• Amneal Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharmaceuticals
• Mylan

Q6. Which glucagon-like peptide 1 agonists market segment will be the largest in future?

Answer: Lucintel forecasts that dulaglutide will remain the largest segment over the forecast period due to growing obesity rates, and increasing genetic risk factors for type 2 diabetes.

Q7. In glucagon-like peptide 1 agonists market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the expansion of research and development, as well as growing healthcare facilities in the region.

Q8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the glucagon-like peptide 1 agonists market by drug type (exenatide, liraglutide, lixisenatide, and dulaglutide), brand (byetta, bydureon, victoza, trulicity, and lyxumia), route of administration (oral, parenteral, and others), end use (hospitals, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?